Approval of Unique High Risk project proposal by KWF

Upon positive assessment of the KWF Unique High Risk project grant application APO-T and the group of dr Paul van Bergen en Henegouwen (UU) start collaboration on project entitled “Generation of nanobodies binding peptide/MHC-l complexes derived from intracellular tumor markers for targeted therapies”. The technology presented in our proposal was described by reviewers as having the potential to revolutionize cancer therapy.